Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 7713 participants.
Also called NCT06930885
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 7,713 participants
- Sponsor
- Registry
-
NCT06930885
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Brazil
- Registry status
- Recruiting
Technical summary
Registry record NCT06930885. Randomized; quadruple masking; primary purpose treatment. Start 2025-06-12 (actual); primary completion 2031-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease
- Acronym
- EPOCA
- Condition
- Atherothrombotic Diseases
- Condition
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Intervention (Drug)
- Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin)
- Intervention (Drug)
- Colchicine 0.5 mg
- Intervention (Drug)
- Usual Care Group
- Intervention (Drug)
- Colchicine-placebo 0.5 mg
- Lead sponsor
- Hospital do Coracao
Record details
- Record id
cardio:ct-nct06930885- Content hash
ff81930827baa28d5eb4f8bacfc3985ce73f8f82a8ccecd0f7c82960ae4be1c3